Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sormani, M. P.
Right arrow Articles by Filippi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sormani, M. P.
Right arrow Articles by Filippi, M.
Related Collections
Right arrow MRI
Right arrow Clinical trials Methodology/study design
Right arrow Multiple sclerosis
Neurology 2001;57:1883-1885
© 2001 American Academy of Neurology
Brief Communications

Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments

M. P. Sormani, PhD, M. Rovaris, MD, F. Bagnato, MD, P. Molyneux, MD, P. Bruzzi, MD, C. Pozzilli, MD, D. H. Miller, MD, G. Comi, MD and M. Filippi, MD

From the Neuroimaging Research Unit (Drs. Sormani, Rovaris, Comi, and Filippi), Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan; Unit of Clinical Epidemiology and Trials (Drs. Sormani and Bruzzi), National Institute for Cancer Research, Genoa; Department of Neuroscience (Drs. Bagnato and Pozzilli), University "La Sapienza," Rome; Italy; and NMR Research Unit (Dr. Molyneux), Institute of Neurology, London, United Kingdom.

Address correspondence and reprint requests to Dr. M. Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy; e-mail: filippi.massimo{at}hsr.it

The authors estimated the sample sizes needed for exploratory trials of MS assessing the efficacy of new treatments in reducing the number of new enhancing lesions vs those of interferon-ß or glatiramer acetate. The sample sizes per arm ranged from 868 (effect: 20%) to 94 (effect: 50%) for patients with relapsing–remitting MS and from 2,484 (effect: 20%) to 361 (effect: 50%) for patients with secondary progressive MS. In MS, exploratory trials of new vs available therapies require large numbers of patients, even when MR end-points are used.




This article has been cited by other articles:


Home page
 NeurologyHome page
M. P. Sormani, M. Rovaris, G. Comi, and M. Filippi
A composite score to predict short-term disease activity in patients with relapsing-remitting MS
Neurology, September 18, 2007; 69(12): 1230 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi
The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials
Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347.
[Abstract] [PDF]

Home page
 Mult SclerHome page
T. F Scott, C. J Schramke, and G. Cutter
Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis
Multiple Sclerosis, June 1, 2003; 9(3): 289 - 292.
[Abstract] [PDF]

Home page
 Am. J. Neuroradiol.Home page
M. Rovaris, G. Comi, D. Ladkani, J. S. Wolinsky, and M. Filippi
Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis
AJNR Am. J. Neuroradiol., January 1, 2003; 24(1): 75 - 81.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.